Adagene Announces Updates to its Board of Directors SAN DIEGO and

Adagene Announces Updates to its Board of Directors

SAN DIEGO and SUZHOU, China, April 28,

2023 - Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming

the discovery and development of novel antibody-based therapies today announced updates to its board of directors (the "Board"),

including the following:

"We are excited to welcome Drs. Turner

and Du and Ms. Wang to our Board, as we work to advance our differentiated clinical products rapidly to reach critical value inflection

points, harvest value from our preclinical assets, and fully leverage our platform technologies to drive future growth," said Peter

Luo, Ph.D., Co-Founder, Chief Executive Officer and Chairman of the Board of Adagene.

"I am also appreciative of Lefei Sun's many contributions during his past four years of service and the contributions of Yuwen

Liu in the past year. I look forward to working with the new directors who bring a breadth of industry experience and new insights to

Adagene Inc. (Nasdaq: ADAG) is a platform-driven,

clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.

Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs.

Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody , SAFEbody , and POWERbody technologies,

Adagene's highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with

reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit: https://investor.adagene.com.

a registered trademark in the United States, China, Australia, Japan, Singapore,

and the European Union.

Safe Harbor Statement

press release contains forward-looking statements, including statements regarding the potential implications of clinical data for patients,

and Adagene's advancement of, and anticipated clinical activities, clinical development, regulatory milestones, and commercialization

of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of

various important factors, including but not limited to Adagene's ability to demonstrate the safety and efficacy of its drug candidates;

the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing

of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene's drug candidates; Adagene's

ability to achieve commercial success for its drug candidates, if approved; Adagene's ability to obtain and maintain protection

of intellectual property for its technology and drugs; Adagene's reliance on third parties to conduct drug development, manufacturing

and other services; Adagene's limited operating history and Adagene's ability to obtain additional funding for operations

and to complete the development and commercialization of its drug candidates; Adagene's ability to enter into additional collaboration

agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene's clinical

development, commercial and other operations, as well as those risks more fully discussed in the "Risk Factors" section in

Adagene's filings with the U.S. Securities and Exchange Commission.

All forward-looking statements are based on information currently available to Adagene,

and Adagene undertakes no obligation to publicly update or revise

any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Investor & Media Contact